✦ LIBER ✦

[494] EARLY HBV-DNA SUPPRESSION DURING TREATMENT WITH LAMIVUDINE FOR HBeAg NEGATIVE CHRONIC HEPATITIS B LEADS TO MAINTENANCE OF RESPONSE UNDER TREATMENT

✍ Scribed by A.S. Hadziyannis; S.J. Hadzivannis

Book ID: 117375588
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 140 KB
Volume: 46
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(07)62092-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early on-treatment prediction of respons

Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels

✍ Vincent Rijckborst; Bettina E. Hansen; Yilmaz Cakaloglu; Peter Ferenci; Fehmi Ta 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 2 views

Ferenci is a consultant for, advises, is on the speakers' bureau of, and received grants from Roche. Dr. Janssen is a consultant for and received grants from Roche, Bristol-Myers Squibb, Schering-Plough, Novartis, and Gilead. Dr. Flisiak received grants from Roche.

Prediction of the response to peg-interf

Prediction of the response to peg-interferon-alfa in patients with HBeAg positive chronic hepatitis B using decline of HBV DNA during treatment

✍ Bettina E. Hansen; Erik H.C.J. Buster; Ewout W. Steyerberg; Emmanuel Lesaffre; H 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 193 KB 👁 2 views

## Abstract Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to d